Nasal Dilators — Body Handbook

Breathing · §20

Nasal Dilators

A nasal dilator — an adhesive strip across the bridge of the nose, or a small frame inserted into the nostrils — physically opens the narrowest part of your airway, the spot where about half your breathing resistance lives. For the right person — a stuffy-nosed sleeper, a pregnant woman with rhinitis, someone whose nostrils collapse inward when they inhale hard — it's a cheap, drug-free, same-night fix. For everyone else, including most snorers and almost everyone with sleep apnea, the effect is much smaller than the marketing suggests.

Do · As-needed Evidence Emerging Chapter Breathing

The mechanical airflow gain is real and immediate — strips and inserts both clear the obstruction at the nasal valve. The downstream story is narrower: a small sleep-quality lift for stuffy noses, a modest snoring reduction for some users, no effect on sleep apnea, and no exercise edge despite the NFL ads of the 1990s. Cheap, OTC, low-effort. Worth a trial if congestion is wrecking your sleep; not the right tool if a partner is reporting gasping pauses, or your daytime is hijacked by fatigue.

The narrowest part of your airway sits about a centimetre inside each nostril — the nasal valve. That single spot generates roughly half of all the resistance your lungs work against when you breathe through the nose. When you inhale hard, the slit gets pulled a little narrower. When allergies, a cold, or a head full of pollen swell the tissue around it, it pulls a lot narrower.

External strips work from the outside in. A springy band held on by adhesive lifts the cartilage outward, like a tiny tent pole over the bridge. Internal dilators work from the inside out — a soft frame seated in each nostril props the valve open and keeps it from collapsing on inhale. Either way the device does one thing: it changes how much air gets through that one slit. It does nothing about a deviated septum further back, swollen turbinates deeper in the nose, or the throat collapsing during sleep. Whatever the obstruction is, the dilator only addresses the part of it that lives at the cartilage joint at the front of your nose.

What they actually do

On a rhinomanometer — the machine that measures how hard it is to push air through your nose — both formats clear the same hurdle and produce the same kind of result. Strips lift airflow by roughly 15 to 30%; inserts can push it higher Dinardi et al. 2014. The airflow change is real, replicated, and instant. What that change does downstream is the more interesting question.

For snoring, the picture is small-but-positive in the right person and roughly zero in everyone else. A randomized trial in chronic-rhinitis snorers found an external strip cut the snoring index by nearly half — but only in the subgroup with measurable congestion at baseline Pevernagie et al. 2000. In unselected snorers, overnight sleep-lab recordings mostly show no meaningful change in how loud or how often Liistro et al. 1998.

For sleep apnea, the answer is no. Apnea is the airway collapsing in your throat — not at the front of your nose — and dozens of overnight studies confirm the dilator doesn't move the apnea index in a way that matters. The American Academy of Sleep Medicine explicitly does not recommend nasal dilators as primary treatment AASM 2006. They show up in the literature mostly as the placebo arm in trials of CPAP, precisely because their effect on apnea is so small Amaro et al. 2012.

For sleep quality — meaning how rested you actually feel — there's a real effect when congestion is the thing wrecking your nights, and not much when it isn't Pevernagie et al. 2000.

For exercise breathing, the literature is unflattering. Sham-controlled trials at submaximal and maximal effort show no improvement in oxygen uptake, time to exhaustion, ventilation, or perceived effort once you're working hard. The reason is mechanical: above roughly 40 litres of air per minute — about the breathing rate of a moderate jog — runners and cyclists switch to breathing through the mouth, and what your nose is doing stops mattering Dinardi et al. 2014.

How to use them

External strips: wash and dry the bridge of your nose — no lotion, no moisturizer, no facial oil left over from the evening. Peel the backing, lay the strip across so the centre spans the valve, about a finger-width above the tip of your nose. Press for ten seconds so the adhesive seats. One strip per night, single use. Pull it off in the morning with warm water on the adhesive — it lifts the strip without dragging on the skin.

Internal dilators: most brands ship with three or four sizes — try the medium first, step up or down if it slips out during sleep or pinches. Insert before bed. Reusable models like Mute and Turbine last one to four weeks of nightly use per device; Nozovent and Airmax run several months with daily soap-and-water cleaning.

If you take blood thinners, skip the internal dilators — putting them in and taking them out can scrape the nostril lining and bleed more than it should. Skip strips on broken skin, active acne on the bridge, or after recent rhinoplasty until your surgeon clears it. And the big one: if a partner is reporting that you stop breathing in your sleep, gasp awake, or that the snoring sounds like it pauses and restarts — get checked for sleep apnea before reaching for the OTC fix.

Three claims worth ignoring

Quieter snoring means treated apnea. It doesn't. The dilator reduces the negative pressure pulling on your soft palate, so the rattle can soften — but the throat still collapses if it's going to collapse. The partner's review and the polysomnograph don't always agree, and the polysomnograph is the one that matters Camacho et al. 2016.

They help you run harder. Breathe Right wrapped itself in NFL endorsements in the mid-1990s, and the claim has outlived the trials. Once you're working hard enough for breathing to matter, you're breathing through your mouth — and what your nose is doing has stopped being the bottleneck Dinardi et al. 2014.

Strips and inserts are the same thing. They aren't. Inserts produce larger airflow gains and modestly better snoring outcomes in pooled trials; strips are easier to put on and more popular. Pick by which one you'll actually use every night, not by the box you've already seen at the pharmacy Camacho et al. 2016.

If a dilator isn't the right tool

If the problem is allergies or chronic stuffiness, the device that opens the valve is downstream of the inflammation that closed it. Steroid nasal sprays — fluticasone and mometasone, sold over the counter — treat the cause; they take a week or two to land but the benefit doesn't vanish when you stop using a strip at night. Saline irrigation with a neti pot or squeeze bottle clears mucus and allergens cheaply. Topical decongestants like oxymetazoline work fast but rebound hard if you use them more than three days running. None of these and a dilator are mutually exclusive — most chronic-rhinitis sufferers end up with two or three of them in rotation.

If the problem is snoring or apnea, dilators are the bottom rung. CPAP is the first-line treatment for diagnosed apnea; oral appliances handle the mild-to-moderate end; sleeping on your side does more than most devices for positional snorers. For structural valve collapse that no strip can compensate, an ENT can offer septoplasty, functional rhinoplasty, or a lateral wall implant.

Why "I tried it and it didn't work"

Three places the dilator quietly fails. Wrong population: someone with undiagnosed apnea wears strips, snores more softly, and feels treated — while the airway is still collapsing every night. The polysomnograph would catch the gap; the bedroom doesn't. Wrong fit: an insert that's too small slips out on the first turn over; too large leaves a pressure mark on the rim. Most brands ship multi-size packs because this is so common. Wrong obstruction: a deep septal deviation or a swollen turbinate sits behind the valve — structural nasal obstruction the dilator was never going to reach — so it pulls open a door that opens onto a wall.

Adhesive failure is the boring one. Moisturizer, facial oil, and sweat all weaken the bond — the strip migrates over the night, lands halfway across one cheek by morning, and the user concludes the product doesn't work. The product worked; the skin prep didn't.

What it costs and where to get it

Strips run roughly thirty to sixty cents each in bulk — about a hundred and fifty dollars a year at nightly use. Every pharmacy stocks them; supermarket and online options are cheaper than the brand name. Inserts run eight to thirty dollars per device, replaced every one to twenty-six weeks depending on brand — about sixty to a hundred and fifty dollars a year. Neither is prescription, neither is covered by insurance, both pack flat for travel.

The practical sequence most people don't get told: try strips first because they're cheap and you'll know in three nights whether anything changed. If they help but the adhesive irritates your skin, switch to internal inserts. If neither does anything noticeable, the bottleneck on your breathing isn't at the valve — congestion, septum, throat, or apnea is the next thread to pull.

What changes if it works

For the right person — a chronic stuffy-noser, a pregnant woman whose nose has been blocked for the second trimester, someone whose partner has been quietly griping about snoring for years — the first night does most of the work. Cool air on the back of the throat that you'd half-forgotten was possible. By the end of the first week, mouth-breathing has dropped enough that morning dry-mouth and sore throat ease off. Partner reports of quieter sleep arrive in the same span Pevernagie et al. 2000.

Past a month, things stabilize: nightly use becomes background, the effect stays roughly where it was, and there's no compound interest. The trade-off is honest. You're not cured. You're getting a mechanical workaround for a mechanical problem, every night you use it — and the night you stop is the night the obstruction comes back.

If you suspect apnea, that's the next thread to pull — separately. If you've found that taping your mouth shut at night helps you, the dilator and the tape usually go together. And if congestion has been with you forever, the question is upstream of the valve: allergies, septum, polyps, the inflammation behind the door rather than the door itself.

Related in the handbook

Helps

— For a mouth-breather whose block is at the nostril, a dilator is a cheap same-night way to get the airflow back to the nose.
— For an allergy-stuffed nose at night, a dilator is a same-night mechanical fix while you treat the underlying rhinitis.
— If a narrow airway is breaking your sleep, a dilator that opens the nose is a low-cost first step.

Alternatives

— Dilators help airflow but don't fix a bent septum or polyps — if they only half-work, look at the structure.
— Both target a stuffy nose without drugs — irrigation clears the cause, a dilator props the airway open; many use both.

— Trying to nose-breathe through workouts? A dilator helps a stuffy nose, though it's no performance edge on its own.
— Before reaching for a dilator, know the nasal cycle — a single blocked nostril at night is often just normal switchover, not obstruction.
— Dilators open the nose but do nothing for apnea. If a partner hears gasping pauses, get screened instead.

Substance and claimed effects

Nasal dilators are mechanical devices that widen the internal nasal valve — the narrowest portion of the nasal airway, where the cartilaginous upper lateral cartilage meets the septum at roughly a 10–15° angle, generating ~50% of total upper-airway resistance in nasal breathers. Two delivery formats dominate: external adhesive strips with embedded spring-steel or plastic bands that lift the lateral alae outward (Breathe Right and generics; OTC-cleared in the United States since 1993), and internal stent-style devices inserted into each nostril that mechanically prop the valve open from within (Nozovent, Mute, Turbine, Max Air, Airmax, various silicone cones). Both formats are FDA-cleared as Class I medical devices intended to reduce snoring, transiently relieve nasal congestion, and improve nasal airflow in adults. Manufacturer and community claims extend beyond the cleared indications to better sleep quality, reduced apnea, easier exercise breathing (especially nasal-only running and cycling), facilitation of mouth-tape adherence, and daytime symptom relief in allergic rhinitis and pregnancy rhinitis. This dossier covers all of these claims holistically — the airflow change is the substance, the downstream consequences across snoring, sleep, exercise, and daytime congestion are the dimensions where the meta scores are set.

Evidence by addressing question

Mechanism

The nasal valve area is a Starling-resistor analogue: airflow through it is governed by transmural pressure and tissue compliance. During inspiration, the negative pressure inside the valve pulls the soft tissue inward — in a compromised or collapse-prone valve (post-rhinoplasty, age-related cartilage weakening, congenitally narrow, congested mucosa, lateral-wall flaccidity demonstrable on the Cottle manoeuvre), this dynamic collapse multiplies static resistance. External strips work by passive lateral traction — the strip's spring band, anchored by adhesive on the skin above each nostril, exerts outward force on the lateral cartilage and reduces the inspiratory collapse. Internal dilators work by intra-luminal stenting — a rigid or semi-rigid frame seated against the inner mucosa holds the valve open through both phases of respiration.

Rhinomanometry and acoustic rhinometry consistently show measurable airflow gains. External strips increase minimum cross-sectional area at the valve by ~15–30% and reduce total nasal resistance by ~12–22% in healthy adults Dinardi et al. 2014. Internal dilators (Nozovent and successors) tend to produce larger objective gains — peak inspiratory flow can rise 25–48% Petruson 1990. The mechanism is purely mechanical — there is no pharmacological component, no vasoconstriction, no mucosal effect. Consequence: a dilator changes flow at the valve and nowhere else. It cannot relieve a congested inferior turbinate, deviated septum behind the valve, polyp, or oropharyngeal collapse — those obstructions sit downstream of where the device acts.

Evidence

Airflow. The mechanical effect is replicated and uncontroversial. Acoustic-rhinometry studies, sham-controlled and crossover, show consistent valve-area increases and resistance reductions across both formats Dinardi et al. 2014. Effect size at the valve is robust; what is contested is whether that local effect translates to clinical outcomes.

Snoring. Polysomnographic and partner-reported trials have produced mixed-positive results. Early Nozovent work in simple snorers showed reductions in snoring frequency and partner-bother scores Petruson 1990. The Pevernagie chronic-rhinitis RCT (n=22, sham-controlled crossover) showed an external dilator reduced snoring index by ~47% in a subset with elevated baseline nasal resistance — but no effect in the non-rhinitic subset Pevernagie et al. 2000. Liistro's polysomnographic study found no significant reduction in snoring loudness or frequency with Breathe Right in unselected snorers Liistro et al. 1998. The 2016 Camacho meta-analysis pooling 15 studies concluded internal dilators show modest snoring reductions, external strips show smaller effects, and neither produces clinically meaningful changes in primary outcomes for most users Camacho et al. 2016.

Obstructive sleep apnea. Negative across the modern literature. The Hoijer et al. 1992 trial in 10 OSA patients showed Nozovent reduced apnea index from 19 to 12 — a promising early signal that did not replicate at scale Hoijer et al. 1992. Subsequent polysomnographic trials, larger and methodologically tighter, found no clinically significant AHI reduction with either device class Liistro et al. 1998. The 2016 meta-analysis confirms: pooled AHI change is small (~−2 events/hour) and not clinically actionable; nasal dilators do not treat OSA Camacho et al. 2016. AASM practice parameters do not recommend nasal dilators as primary therapy for OSA Morgenthaler et al. 2006 (AASM). They have a separate evidentiary role as a sham/placebo arm in CPAP trials precisely because their effect on AHI is so small Amaro et al. 2012.

Sleep quality. Distinct from snoring or AHI: subjective sleep-quality measures (Pittsburgh Sleep Quality Index, partner-rated restfulness) improve in chronic-rhinitis populations using nasal dilators Pevernagie et al. 2000. In healthy non-congested sleepers, the subjective effect is small and largely captured by placebo response in sham-controlled designs Amaro et al. 2012.

Exercise breathing. Trial literature is consistent and unflattering for performance claims. Submaximal and maximal exercise trials with external nasal strips show no improvement in VO₂max, time to exhaustion, ventilation, blood lactate, or perceived exertion at high intensities. Effects on rating of perceived exertion at submaximal effort are inconsistent — some trials show small reductions, others none. The proposed mechanism (lower work of breathing) breaks down at exercise intensities where ventilation crosses ~40 L/min: at that point most athletes oronasally breathe, and nasal flow ceases to be rate-limiting Dinardi et al. 2014. The genuine use case at exercise is comfort during nasal-only breathing protocols, not performance.

Daytime congestion. Symptomatic relief is real and immediate — the device mechanically opens the valve while worn. Effect persists only while the device is in place; there is no carry-over. Useful in: pregnancy rhinitis (drug-free alternative when topical decongestants are contraindicated), nocturnal allergic rhinitis, post-cold congestion. Not a substitute for treating the underlying inflammation or obstruction.

Protocol

Dose: one device per nasal cycle of use. External strips: clean the skin (no lotion), apply across the nasal bridge so the central plastic spans the valve, press 5–10 seconds. One strip per night, single use, removed gently in the morning (warm water softens the adhesive). Internal dilators: sized to nostril width (most brands ship multi-size packs); insert before sleep; brands like Mute and Turbine are reusable for ~1–4 weeks of nightly use; Nozovent and Airmax are reusable for ~6 months with cleaning. Cleaning: warm soapy water daily.

Indication selection — the dossier evidence supports use in three contexts: positional or rhinitis-associated snoring with a partner complaint; nasal congestion (allergic, vasomotor, pregnancy, post-cold) interfering with sleep; and as a comfort aid for nasal-breathing protocols (mouth-taping adherence, nasal-only running). For OSA, AASM 2006 guidance applies — nasal dilators are not primary therapy Morgenthaler et al. 2006.

Contraindications

External strips: adhesive sensitivity / dermatitis; broken skin or active acne on the bridge; recent rhinoplasty (avoid until cleared by surgeon); facial dermatosis. Internal dilators: bleeding diatheses or anticoagulant therapy (mucosal trauma risk on insertion); severe deviated septum where insertion is mechanically blocked; recent nasal surgery; chronic epistaxis. Both: not OSA therapy. A diagnosed OSA patient using a dilator instead of CPAP or alternative therapy is undertreating the disease.

Misconceptions

The dominant misconception is that snoring volume reduction equates to apnea treatment. Snoring originates at the soft palate and oropharynx; apnea is upper-airway collapse, predominantly at the same site. Reducing nasal resistance reduces the negative downstream pressure that contributes to palatal flutter — so the snoring sound may soften without the airway collapse pattern changing. Patients and partners both interpret quieter sleep as treated sleep; the polysomnograph does not agree Camacho et al. 2016.

The second misconception is the exercise claim — Breathe Right strips were heavily marketed via NFL endorsements in the mid-1990s. Trial data does not support performance enhancement at the intensities where competitive athletics happens. The mechanism breaks at oronasal-switching ventilation rates.

The third misconception is conflating internal and external dilators in evidence discussions. Internal dilators produce larger objective airflow gains and meta-analytically larger snoring reductions; external strips are more convenient but show smaller effects Camacho et al. 2016. Aggregated "nasal dilator" claims paper over a real device-class gap.

Alternatives

For nocturnal nasal obstruction: intranasal corticosteroids (fluticasone, mometasone) treat the inflammatory cause when rhinitis drives obstruction — slower onset (1–2 weeks) but addresses pathophysiology rather than masking it. Saline irrigation (neti pot, squeeze bottle) clears mucus and allergen load. Topical decongestants (oxymetazoline) work fast but cause rebound congestion after 3–5 days of continuous use. For OSA: CPAP is first-line; oral appliances for mild-moderate disease; positional therapy for positional OSA; weight loss; surgery (UPPP, hypoglossal nerve stimulation, maxillomandibular advancement) in select cases. For mouth-breathing habit: myofunctional therapy, mouth taping (with appropriate workup), orthodontic correction if airway-narrowed. Septoplasty / functional rhinoplasty / lateral wall implants (Latera) for structural valve collapse.

Failure modes

The most common failure is wrong-population use: someone with OSA wearing strips and getting partner reports of softer snoring assumes they are being treated. Polysomnography would catch the gap; in primary care it often is missed. The second failure is sizing — internal dilators that are too small slip out during sleep, too large cause pressure ulceration of the columella or alar rim. The third is adhesive failure on strips — facial oils, moisturizers, and sweat all reduce adhesion; the strip migrates or detaches and the user concludes "didn't work." The fourth is mucosal drying with internal devices in low-humidity bedrooms (heated indoor air) — the always-open valve increases evaporative water loss from the mucosa, producing morning crusting and rebound congestion. The fifth is structural mismatch: a deeply deviated septum, large turbinates, or polyps sit downstream of the valve, so a dilator does no useful work; the airway is still occluded behind the gain.

Practicalities

External strips: ~$0.30–0.60 per strip in bulk; ~$110–220/year at nightly use. Available at every pharmacy, supermarket, OTC online. Internal dilators: ~$8–30 per device for reusable models, replaced every 1–6 months depending on brand; annual cost ~$60–150 at nightly use. No prescription, no insurance coverage. Setup time: under a minute. Travel-friendly. The decision matrix in practice: strips for trial use and adhesive-tolerant users; internal devices for sustained nightly use and users who find strips ineffective or irritating.

History

Nozovent (Petruson, Sweden) and Breathe Right (CNS Inc., Minnesota, US) emerged within years of each other in the late 1980s and early 1990s. Bruce Johnson, the inventor of Breathe Right, was a chronic nasal-obstruction sufferer; FDA OTC clearance came in 1993 and NFL adoption followed in 1994, driving the brand to mass awareness. The internal-dilator category fragmented in the 2010s as silicone-manufacturing costs fell — Mute (Rhinomed, Australia), Turbine, Max Air, and Airmax all reach consumer markets, each iterating on the cone-frame geometry. The category has not produced a transformative new entrant; the physics ceiling at the nasal valve is fixed.

Stakes

If chronic nocturnal nasal obstruction is left untreated, the felt-experience trajectory is mouth-breathing-dominated sleep — dry mouth on waking, morning sore throat, snoring complaints from partners that escalate over years, and the metabolic-cardiovascular sequelae of fragmented sleep regardless of formal AHI diagnosis. Untreated allergic rhinitis is associated with reduced sleep quality and daytime fatigue independent of asthma; the dilator addresses the mechanical component of the symptom without treating the inflammation.

Payoff

For the right population — chronic rhinitis sleepers, snorers with valve-collapse component, mouth-tape adopters needing nasal-airway confidence — the felt change is same-night. Partner reports of quieter sleep arrive within a week. The polysomnographic shift is small; the subjective shift can be substantial in obstructed users Pevernagie et al. 2000. For unobstructed sleepers, no felt change.

The credibility range

Optimist case

The mechanical effect is real, replicated, and immediate. For users with documented nasal-valve compromise — confirmed by Cottle manoeuvre, rhinomanometry, or simple symptomatic rhinitis — dilators produce measurable airflow gains, partner-confirmed snoring reductions, and sleep-quality improvements that map onto reduced morning congestion and dryness. They are drug-free, cheap, OTC, and contraindication-light. They are a legitimate first-line trial for snoring before workup, a useful adjunct in pregnancy rhinitis where pharmacotherapy is constrained, and a reasonable comfort aid for mouth-tape adherence and nasal-only exercise. The literature underestimates the benefit because trials enrolled unselected populations; trials in pre-screened rhinitis or valve-collapse subgroups show larger effects.

Skeptic case

Polysomnographic outcomes are unflattering across the literature. AHI does not move clinically. Snoring frequency and loudness changes are small in aggregate and inconsistent across trials. The placebo response in snoring is huge — partners and self-reporters are unreliable judges of nocturnal sound — and sham-controlled trials wash out much of the apparent effect. The exercise-performance claim does not survive any sham-controlled trial at meaningful intensities. The OSA marketing claim is actively harmful where it delays diagnosis. Commercial incentives from a billion-dollar OTC category produce a steady drumbeat of underpowered, industry-adjacent positive trials and consumer-facing claims that overshoot the data.

Author's call

Modest, well-evidenced, narrowly useful. The mechanism is real; the airflow gain is real; the snoring effect is real but small at the population level. The dominant evidence-based use is symptomatic congestion relief, particularly in chronic rhinitis and pregnancy, where the device addresses a mechanical contribution to nocturnal obstruction. Snoring use cases are reasonable as a first-line trial when the snorer is otherwise low-risk; in screened OSA, dilators are inadequate. Exercise claims fail. The entry should land as a legitimate-but-narrow tool — score health_short_term and sleep modestly, longevity zero, energy and focus near-zero except as downstream of better sleep in the right population. Evidence rating moderate (good airflow data, weaker outcome data); controversy low (field largely agrees on the modest-effect framing).

Stakeholder and incentive map

Commercial. GSK (Breathe Right, acquired from CNS in 2006), Rhinomed (Mute), various silicone-device startups. Total category ~$200M+ annually. Marketing has historically overshot the evidence — NFL endorsement era, exercise-performance claims, snore-cure framing.
Clinical / professional. ENT and sleep medicine treat the category as adjunctive: useful in select cases, not primary therapy. AASM does not endorse for OSA Morgenthaler et al. 2006. Obstetricians and allergists are most likely to recommend, because their patient populations (pregnant, rhinitic) are where the device's narrow indication is strongest.
Community. The mouth-tape / nasal-breathing community (popularised by Nestor's Breath, the Buteyko methodology, and the "always nose-breathe" wellness corner) drives renewed interest in internal dilators as an adjunct.
Skeptic / counter. Sleep specialists are vigilant against delayed OSA diagnosis. The exercise-science community has been consistently negative on performance claims.

Population variability

Responders. Adults with chronic rhinitis, structural valve compromise (post-rhinoplasty, age-related cartilage weakness, lateral-wall flaccidity), pregnancy rhinitis, allergic rhinitis seasons. Pevernagie's responders showed a ~47% snoring reduction; non-responders showed nothing Pevernagie et al. 2000.
Non-responders. Healthy unobstructed sleepers; OSA patients with predominantly oropharyngeal collapse; severe deviated septum (obstruction is behind the valve); large adenoids in pediatric populations.
Pediatric. Not standard. Smaller anatomy, different obstruction patterns (adenotonsillar predominance). Sizing is the practical barrier.
Pregnancy. Specifically supported — pregnancy rhinitis affects ~20% of pregnancies, topical decongestants are time-limited and class-C, intranasal steroids carry mild caution; mechanical dilation is a clean first-line option.
Older adults. Cartilage weakening makes valve collapse more common with age; this is one of the populations most likely to benefit from dilators in stable mild snoring.

Knowledge gaps

The literature is dominated by short-duration polysomnographic trials in mixed populations; large-N trials pre-screened for valve-collapse or chronic-rhinitis status would clarify the responder phenotype but are not commercially incentivised. Long-term adherence and outcome data is thin — most trials run 1–2 weeks. Internal-dilator literature is sparser than external-strip literature, and head-to-head comparisons are few. The interaction with mouth-taping is under-studied despite community adoption. Sham-controlled exercise data is reasonably consistent on negative-performance findings but rarely measures comfort or downstream nasal-only protocol adherence, which is where the actual user benefit may sit.

Scope coverage vs. brief. The brief named nasal airflow, snoring, sleep quality, exercise breathing, and daytime congestion. All five are covered end to end. Exercise lands in evidence and misconceptions rather than its own section because the honest answer is negative — wrapping it in a dedicated subsection would over-feature a non-effect.

Hard call on sleep score. Considered sleep:1 versus sleep:2. Landed on 2 because in the responder phenotype (chronic-rhinitis sleepers, ~20%+ of pregnant women, allergic seasons) the felt sleep effect is clearly real and trial-backed (Pevernagie 2000), not just trivial. The score is for the substance in its proper context, not for the average reader. Pitch language hedges accordingly.

Hard call on energy score. Considered 0. Kept at 1 because the indirect mornings-feel-better effect in the responder population is genuine, even if narrow. Pitch is explicitly conditional on stuffy-nights being the bottleneck.

Cadence. Chose as-needed over daily because the device is recommended use-when-indicated (congestion, snoring, mouth-tape adherence), not as a universal nightly habit. A pregnant rhinitis sufferer may use it nightly for a trimester; a cold sufferer for a week; an unobstructed sleeper not at all.

Contraindications. Only blood-thinners from the closed vocabulary applies cleanly (insertion bleeding risk on internal dilators). Adhesive sensitivity, recent rhinoplasty, and structural anatomy issues are flagged in prose because no closed-vocab token covers them.

Excluded from scope. CPAP, oral appliances, septoplasty, lateral wall implants, intranasal corticosteroids, mouth taping all get their own entries (named in alternatives). Pediatric use deliberately set aside — different anatomy, adenotonsillar obstruction dominant, and sizing is the practical barrier; would warrant a paediatric-airway entry separately.

Future-link candidates. Once they exist: mouth-tape, obstructive-sleep-apnea, cpap, allergic-rhinitis, pregnancy-rhinitis, septal-deviation, nasal-breathing-vs-mouth-breathing. Related field left empty for now — no published siblings to point at.

Separate-entry candidates surfaced. Lateral wall implants (Latera) and functional rhinoplasty are real category gaps but warrant a "structural valve surgery" entry rather than being squeezed into alternatives.

Citation set is deliberately narrow. Eight refs anchoring the load-bearing claims: Petruson 1990 (Nozovent airflow), Hoijer 1992 (early OSA trial), Liistro 1998 (PSG snoring), Pevernagie 2000 (RCT in rhinitis), Morgenthaler/AASM 2006 (guideline non-recommendation), Amaro 2012 (placebo-arm use), Dinardi 2014 (review of airflow effects), Camacho 2016 (meta-analysis). Industry-positive small trials excluded as not load-bearing.